Aprea Therapeutics stock recorded a second consecutive surge, jumping another 22%, while Capricor Therapeutics also saw its stock surge following an upgrade from Oppenheimer. These movements indicate positive investor sentiment for both pharmaceutical companies.

Aprea Therapeutics reported a GAAP EPS of -$0.07, surpassing estimates by $0.16, while PolyPid announced a GAAP EPS of -$0.35, beating expectations by $0.03.

Aprea Therapeutics reported a GAAP EPS of -$0.32, surpassing analyst estimates by $0.07 for the recent financial period.